Comparative Study Of Clinical Effect On Treatment Of Hyperlipemia With Micro-powder Of Lipid-reducing Hongqu

Objective: To observe the therapeutic effect and security on treatment of hyperlipemia with different doses of micro-powder of lipid-reducing Hongqu(MLH), and provide scientific proof for its clinical application and development. Methods: 80 cases of hyperlipemia patients were divided randomly into 4 groups: 21 cases in Group A (MLH of 1/2 dose group), 20 cases in Group B(MLH of full dose group),19 cases in Group C(rough-powder of lipid-reducing Hongqu group) and 20 cases in group D(Xuezhikang group). To observe the changes of clinical symptoms, blood lipid , anti-oxidation, secretion function of vascular endothelium and endothelium-dependent relaxing function of brachial artery. Results: After 50 days of treatment, clinical symptoms improved in all groups, and the significant effective rate and total effective rate to tiredness of A and B groups were superior to those of C and D groups. TC in all groups reduced remarkably, and other laboratory indexes improved with different extent in each group. Total effective rate of A and B groups in reducing lipid was superior to that of C group. TG reduced and CGRP elevated in group A. Endothelium-dependent diastolic function of brachial artery improved and ET/CGRP reduced in A and D groups. Conclusion: MLH had such merits: confirmative lipid-reducing effect, relieving clinical symptoms remarkably and safely, anti-oxidation and protecting vascular endothelium. Its dose was half of the normal, and, deserved to be spread and applied.